Cara Therapeutics, Inc. (0HTC.L)

USD 0.25

(-1.15%)

Total Debt Summary of Cara Therapeutics, Inc.

  • Cara Therapeutics, Inc.'s latest annual total debt in 2023 was 43.16 Million USD , up 2150.63% from previous year.
  • Cara Therapeutics, Inc.'s latest quarterly total debt in 2024 Q2 was 47.16 Million USD , down -83.51% from previous quarter.
  • Cara Therapeutics, Inc. reported annual total debt of 1.91 Million USD in 2022, down -47.78% from previous year.
  • Cara Therapeutics, Inc. reported annual total debt of 3.67 Million USD in 2021, down -30.37% from previous year.
  • Cara Therapeutics, Inc. reported quarterly total debt of 47.16 Million USD for 2024 Q2, down -83.51% from previous quarter.
  • Cara Therapeutics, Inc. reported quarterly total debt of 43.16 Million USD for 2023 FY, up 2150.63% from previous quarter.

Annual Total Debt Chart of Cara Therapeutics, Inc. (2023 - 2011)

Historical Annual Total Debt of Cara Therapeutics, Inc. (2023 - 2011)

Year Total Debt Total Debt Growth
2023 43.16 Million USD 2150.63%
2022 1.91 Million USD -47.78%
2021 3.67 Million USD -30.37%
2020 5.27 Million USD 22.13%
2019 4.31 Million USD 0.0%
2018 - USD 0.0%
2017 - USD 0.0%
2016 - USD 0.0%
2015 - USD 0.0%
2014 - USD 0.0%
2013 - USD -100.0%
2012 780 Thousand USD 3.59%
2011 753 Thousand USD 0.0%

Peer Total Debt Comparison of Cara Therapeutics, Inc.

Name Total Debt Total Debt Difference
Editas Medicine, Inc. 36.53 Million USD -18.149%
Dynavax Technologies Corporation 256.91 Million USD 83.198%
Supernus Pharmaceuticals, Inc. 41.52 Million USD -3.949%
Perrigo Company plc 4.07 Billion USD 98.94%
Illumina, Inc. 2.26 Billion USD 98.092%
Thermo Fisher Scientific Inc. 34.91 Billion USD 99.876%
Iovance Biotherapeutics, Inc. 1 Million USD -4216.7%
Walgreens Boots Alliance, Inc. 9.55 Billion USD 99.548%
IQVIA Holdings Inc. 14.23 Billion USD 99.697%
Heron Therapeutics, Inc. 173.75 Million USD 75.156%
Regeneron Pharmaceuticals, Inc. 2.7 Billion USD 98.403%
Unity Biotechnology, Inc. 26.99 Million USD -59.937%
Waters Corporation 2.35 Billion USD 98.167%
Biogen Inc. 7.33 Billion USD 99.412%
Sangamo Therapeutics, Inc. 38.1 Million USD -13.287%
Evolus, Inc. 126.54 Million USD 65.888%
Adicet Bio, Inc. 17.7 Million USD -143.84%
bluebird bio, Inc. 330.32 Million USD 86.932%
Esperion Therapeutics, Inc. 540.94 Million USD 92.02%
FibroGen, Inc. 170.45 Million USD 74.675%
Agilent Technologies, Inc. 2.73 Billion USD 98.422%
Corbus Pharmaceuticals Holdings, Inc. 20.88 Million USD -106.697%
Homology Medicines, Inc. 44.05 Million USD 2.013%
Geron Corporation 85.89 Million USD 49.747%
Alnylam Pharmaceuticals, Inc. 2.39 Billion USD 98.2%
Amicus Therapeutics, Inc. 445.05 Million USD 90.301%
Myriad Genetics, Inc. 145 Million USD 70.23%
Viking Therapeutics, Inc. 1.26 Million USD -3325.952%
Intellia Therapeutics, Inc. 115.34 Million USD 62.576%
Zoetis Inc. 6.8 Billion USD 99.365%
Abeona Therapeutics Inc. 4.4 Million USD -880.622%
Mettler-Toledo International Inc. 2.16 Billion USD 98.009%
BioMarin Pharmaceutical Inc. 1.13 Billion USD 96.193%
Vertex Pharmaceuticals Incorporated 808.4 Million USD 94.66%
Kala Pharmaceuticals, Inc. 36.32 Million USD -18.842%
Ionis Pharmaceuticals, Inc. 1.45 Billion USD 97.03%
Atara Biotherapeutics, Inc. 57.87 Million USD 25.41%
Verastem, Inc. 41.55 Million USD -3.874%
Nektar Therapeutics 230.4 Million USD 81.264%
Axsome Therapeutics, Inc. 186.37 Million USD 76.838%
Aclaris Therapeutics, Inc. 3.07 Million USD -1304.262%
Sarepta Therapeutics, Inc. 1.39 Billion USD 96.91%
OPKO Health, Inc. 326.56 Million USD 86.781%
Exelixis, Inc. 189.94 Million USD 77.274%
Neurocrine Biosciences, Inc. 428.4 Million USD 89.924%
Corcept Therapeutics Incorporated 151 Thousand USD -28487.417%
Anavex Life Sciences Corp. - USD -Infinity%
uniQure N.V. 138.4 Million USD 68.812%
Imunon, Inc. 1.13 Million USD -3688.929%
Blueprint Medicines Corporation 774.12 Million USD 94.424%
Insmed Incorporated 1.2 Billion USD 96.415%
Halozyme Therapeutics, Inc. 1.49 Billion USD 97.121%
Agios Pharmaceuticals, Inc. 56.98 Million USD 24.252%
TG Therapeutics, Inc. 110.79 Million USD 61.039%
Incyte Corporation 38.28 Million USD -12.746%
Emergent BioSolutions Inc. 877.5 Million USD 95.081%